Morgan Stanley analyst Erin Wright raised the firm’s price target on Cardinal Health (CAH) to $127 from $119 and keeps an Overweight rating on the shares. After Cardinal raised its FY25 EPS guidance to $7.75-$7.90 from $7.55-$7.70, the firm tells investors in a post-earnings recap that it was “pleased by the notable F1Q operational upside and guidance lift with broad-based strength across core pharma subsegments.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health price target raised to $124 from $119 at Deutsche Bank
- Cardinal Health price target raised to $120 from $110 at Mizuho
- Cardinal Health price target raised to $133 from $117 at Barclays
- Cardinal Health Reports Strong Q1 FY2025 Results
- Early notable gainers among liquid option names on November 1st